Microbiota and gut-liver axis: Their influences on obesity and obesity-related liver disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 56, Issue 5, 2013, Pages 461-468

  Vajro, Pietro ^a,b   Paolella, Giulia ^a,b   Fasano, Alessio ^c  

^a UNIVERSITY OF SALERNO   (Italy)

^b ELFID   (Italy)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Gut dysbiosis; Gut liver axis; Inflammasome; Intestinal permeability; Nonalcoholic fatty liver disease; Zonulin

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; ENDOCANNABINOID; INFLAMMASOME; LIPOPOLYSACCHARIDE;

ADIPOSE TISSUE; BACTERIAL TRANSLOCATION; BACTERIOSTASIS; FATTY LIVER; HUMAN; IMMUNE RESPONSE; INTESTINE FLORA; INTESTINE LYMPHATIC TISSUE; INTESTINE MUCOSA PERMEABILITY; LIPID DIET; LIVER DISEASE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; VITAMIN DEFICIENCY;

ADIPOSE TISSUE; ANIMALS; FATTY LIVER; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL MUCOSA; LIPOPOLYSACCHARIDES; LIVER; METAGENOME; OBESITY;

BACTERIA (MICROORGANISMS);

EID: 84877058262     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318284abb5     Document Type: Review

References (51)

1. Volta U, Bonazzi C, Bianchi FB, et al. IgA antibodies to dietary antigens in liver cirrhosis. Ric Clin Lab 1987;17:235-42
2. Ilan Y. Leaky gut and the liver: A role for bacterial translocation in nonalcoholic steatohepatitis. World J Gastroenterol 2012;18: 2609-18
3. Fasano A. Zonulin and its regulation of intestinal barrier function: The biological door to inflammation, autoimmunity, and cancer. Physiol Rev 2011;91:151-75
4. Szabo G, Mandrekar P, Dolganiuc A. Innate immune response and hepatic inflammation. Semin Liver Dis 2007;27:339-50
5. Mehal WZ. The gut-liver axis: A busy two-way street. Hepatology 2012;55:1647-9
6. Sekirov I, Russell SL, Antunes LC, et al. Gut microbiota in health and disease. Physiol Rev 2010;90:859-904
7. Sellitto M, Bai G, Serena G, et al. Proof of concept of microbiomemetabolome analysis and delayed gluten exposure on celiac disease autoimmunity in genetically at-risk infants. PLoS One 2012;7: E33387
8. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-Associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-31
9. Bruel L, Sulzenbacher G, CerveraTison M, et al. a-Galactosidase/ sucrose kinase (AgaSK), a novel bifunctional enzyme from the human microbiome coupling galactosidase and kinase activities. J Biol Chem 2011;286:40814-23
10. Santacruz A, Marcos A, Wärnberg J, et al. EVASYON Study Group. Interplay between weight loss and gut microbiota composition in overweight adolescents. Obesity (Silver Spring) 2009;17:1906-15
11. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003;37:343-50
12. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012;143:913-6
13. Moreno-Navarrete JM, Sabater M, Ortega F, et al. Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-Associated insulin resistance. PLoS One 2012;7:e37160
14. Li JV, Ashrafian H, Bueter M, et al. Metabolic surgery profoundly influences gut microbial-host metabolic cross-Talk. Gut 2011;60:1214-23
15. Musso G, Gambino R, Cassader M. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: Mechanisms and implications for metabolic disorders. Curr Opin Lipidol 2010;21:76-83
16. Maier IB, Stricker L, Ozel Y, et al. A low fructose diet in the treatment of pediatric obesity: A pilot study. Pediatr Int 2011;53:303-8
17. Ebbeling CB, Feldman HA, Chomitz VR, et al. A randomized trial of sugar-sweetened beverages and adolescent body weight. N Engl J Med 2012;367:1407-16
18. Karlsson CL, Onnerfält J, Xu J, et al. The microbiota of the gut in preschool children with normal and excessive body weight. Obesity (Silver Spring) 2012;20:2257-61
19. Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004;101:15718-23
20. Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7:691-701
21. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009;49:1877-87
22. Harte AL, da Silva NF, Creeley SJ, et al. Elevated endotoxin levels in non-Alcoholic fatty liver disease. J Inflamm (Lond) 2010;7:15
23. Goldblum SE, Rai U, Tripathi A, et al. The active Zot domain (aa 288-293) increases ZO-1 and myosin 1C serine/threonine phosphorylation, alters interaction between ZO-1 and its binding partners, and induces tight junction disassembly through proteinase activated receptor 2 activation. FASEB J 2011;25:144-58
24. Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: Crosstalk between the liver and gut. J Physiol 2012;590:447-58
25. Wagnerberger S, Spruss A, Kanuri G, et al. Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. Br J Nutr 2012;107:1727-38
26. Spruss A, Kanuri G, Stahl C, et al. Metformin protects against the development of fructose-induced steatosis in mice: Role of the intestinal barrier function. Lab Invest 2012;92:1020-32
27. Volynets V, Machann J, Küper MA, et al. A moderate weight reduction through dietary intervention decreases hepatic fat content in patients with non-Alcoholic fatty liver disease (NAFLD): A pilot study. Eur J Nutr 2013;52:527-35
28. Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012;482:179-85
29. Dumas ME, Barton RH, Toye A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulinresistant mice. Proc Natl Acad Sci U S A 2006;103:12511-6
30. Fuchs M. Non-Alcoholic fatty liver disease: The bile acid-Activated farnesoid x receptor as an emerging treatment target. J Lipids 2012; 2012:934396
31. Wang PY, Caspi L, Lam CK, et al. Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production. Nature 2008; 452:1012-6
32. Cluny NL, Reimer RA, Sharkey KA. Cannabinoid signaling regulates inflammation and energy balance: The importance of the brain-gut axis. Brain Behav Immun 2012;26:691-8
33. Kirpich IA, Solovieva NV, Leikhter SN, et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: A pilot study. Alcohol 2008;42:675-82
34. Zhu L, Baker SS, Gill C, et al. Characterization of the gut microbiome in non-Alcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology 2013;57:601-9
35. Huang JS, Barlow SE, Quiros-Tejeira RE, et al. Childhood obesity for pediatric gastroenterologists. J Pediatr Gastroenterol Nutr 2013;56:99-109
36. Socha P, Horvath A, Vajro P, et al. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: A systematic review. J Pediatr Gastroenterol Nutr 2009;48:587-96
37. Chalasani N, Younossi Z, Lavine JE, et al. American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterology The diagnosis and management of non-Alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012;142:1592-609
38. Sajjad A, Mottershead M, Syn WK, et al. Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-Alcoholic steatohepatitis. Aliment Pharmacol Ther 2005;22:291-9
39. Million M, Angelakis E, Paul M, et al. Comparative meta-Analysis of the effect of Lactobacillus species on weight gain in humans and animals. Microb Pathog 2012;53:100-8
40. Murphy EF, Cotter PD, Hogen A, et al. Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity. Gut 2013;62:220-6
41. Gøbel RJ, Larsen N, Jakobsen M, et al. Probiotics to obese adolescents; RCT examining the effects on inflammation and metabolic syndrome. J Pediatr Gastroenterol Nutr 2012;55:673-8
42. Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 2008;49:821-30
43. Esposito E, Iacono A, Bianco G, et al. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr 2009;139:905-11
44. Lee HY, Park JH, Seok SH, et al. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet induced obese mice. Biochim Biophys Acta 2006;1761:736-44
45. Yadav H, Jain S, Sinha PR. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition 2007;23:62-8
46. Lirussi F, Mastropasqua E, Orando S, et al. Probiotics for non-Alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007;1:CD005165
47. Loguercio C, De Simone T, Federico A, et al. Gut-liver axis: A new point of attack to treat chronic liver damage? Am J Gastroenterol 2002; 97:2144-6
48. Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005;39:540-3
49. Aller R, De Luis DA, Izaola O, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011; 15:1090-5
50. Vajro P, Mandato C, Licenziati MR, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011;52:740-3
51. Parnell JA, Reimer RA. Prebiotic fiber modulation of the gut microbiota improves risk factors for obesity and the metabolic syndrome. Gut Microbes 2012;3:29-34